Early Allogeneic HCT for Relapsed/Refractory High-Grade Myeloid Neoplasms

Phase 2, open-label, single-arm trial of allogeneic hematopoietic stem cells in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by University of Washington. Primary endpoints: Feasibility of Early Allogeneic Hematopoietic Cell Transplant Assessed by Enrollment and Incidence of Early Transplant and Feasibility of Early Allogeneic Hematopoietic Cell Transplant Assessed by Relapsed-free Survival 6 Months After Transplant. Started Sep 2016; status: completed.